November 28, 2012

BioAxone BioSciences celebrates official opening of clinical and research operations in Cambridge, Mass.

Industry leaders and local officials gather to welcome BioAxone to Massachusetts: From left to right - Kelly Thompson Clark, President & CEO, Cambridge Chamber of Commerce; Angus McQuilken, Vice President for Marketing and Communications, Massachusetts Life Sciences Center; Kelda Rawlings, Director of North American Sales, Arrayjet; Peter Abair, Director of Economic Development and Global Affairs, MassBio; Tim Rowe, Founder & CEO, CIC; Parth Pathak, Jr., Consultant, Regulatory Affairs and Quality, Qserve America Inc.; Kristen McCosh, Commissioner for Persons with Disabilities, City of Boston; Dr. Lisa McKerracher, CEO, BioAxone.
Industry leaders and local officials gather to welcome BioAxone to Massachusetts: From left to right – Kelly Thompson Clark, President & CEO, Cambridge Chamber of Commerce; Angus McQuilken, Vice President for Marketing and Communications, Massachusetts Life Sciences Center; Kelda Rawlings, Director of North American Sales, Arrayjet; Peter Abair, Director of Economic Development and Global Affairs, MassBio; Tim Rowe, Founder & CEO, CIC; Parth Pathak, Jr., Consultant, Regulatory Affairs and Quality, Qserve America Inc.; Kristen McCosh, Commissioner for Persons with Disabilities, City of Boston; Dr. Lisa McKerracher, CEO, BioAxone.

BioAxone BioSciences, a privately held biotechnology company, celebrated on Nov. 28, 2012, the opening of its scientific and clinical headquarters in Cambridge, Mass., as well as its selection this week by Windhover Conferences as one of the “Top Ten” Neuroscience Companies for Partnership. BioAxone, headquartered in Florida, is developing a protein therapeutic drug called Cethrin to improve patient recovery from spinal cord injury. Its scientific and clinical headquarters will be located at the Cambridge Innovation Center in Cambridge, Mass., which was selected for its concentration of life sciences companies, availability of walk-in wet-lab incubator space and its skilled workforce. Dr. McKerracher will be starting operations in Cambridge, with plans to hire 12 employees by 2013.